Napo pharmaceuticals, a jaguar health company, submits investigational new drug (ind) application to fda for microvillus inclusion disease

Mvid is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea san francisco, ca / accesswire / june 28, 2023 / napo pharmaceuticals inc., a jaguar health, inc. (nasdaq:jagx) company, today announced the submission of an investigational new drug (ind) application to the u.s. food and drug administration (fda) for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (mvid). "i am very happy that we have submitted the ind for crofelemer powder for oral solution for the treatment of mvid, an ultra-rare congenital diarrheal disorder (cdd)," said lisa conte, jaguar's president and ceo.
JAGX Ratings Summary
JAGX Quant Ranking